

Title (en)

USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF TUMORS

Title (de)

VERWENDUNG VON ANTI-PD-1-ANTIKÖRPER ZUR BEHANDLUNG VON TUMOREN

Title (fr)

UTILISATION D'ANTICORPS ANTI-PD-1 DANS LE TRAITEMENT DE TUMEURS

Publication

EP 4104856 A4 20240626 (EN)

Application

EP 21753897 A 20210210

Priority

- CN 202010090829 A 20200213
- CN 2021076456 W 20210210

Abstract (en)

[origin: EP4104856A1] The present invention relates to use of an anti-PD-1 antibody in the treatment of melanoma. The present invention also relates to use of an agent for detecting BRAF, NRAS, and CDK4/CCND1 gene mutations in a detection kit for predicting the therapeutic effect of an anti-PD-1 antibody and/or an antigen-binding fragment thereof administered alone to a patient with melanoma.

IPC 8 full level

A61K 39/395 (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: CN EP US)

A61K 31/506 (2013.01 - CN EP US); **A61K 31/519** (2013.01 - CN EP US); **A61K 39/3955** (2013.01 - US); **A61K 39/39558** (2013.01 - CN); **A61P 35/00** (2018.01 - CN EP); **A61P 35/04** (2018.01 - CN EP US); **C07K 16/2818** (2013.01 - CN EP US); **C12Q 1/6886** (2013.01 - CN EP US); **A61K 2039/505** (2013.01 - CN EP); **A61K 2039/545** (2013.01 - US); **C07K 2317/565** (2013.01 - CN US); **C07K 2317/76** (2013.01 - CN US); **C12Q 1/6869** (2013.01 - US); **C12Q 2600/106** (2013.01 - CN EP US); **C12Q 2600/156** (2013.01 - CN EP US)

C-Set (source: CN)

1. **A61K 39/39558 + A61K 2300/00**
2. **A61K 31/519 + A61K 2300/00**
3. **A61K 31/506 + A61K 2300/00**

Citation (search report)

- [A] WO 2016176504 A1 20161103 - BRISTOL MYERS SQUIBB CO [US]
- [X] TANG BIXIA ET AL: "Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 12, no. 1, 14 January 2019 (2019-01-14), pages 1 - 15, XP055878671, Retrieved from the Internet <URL:http://link.springer.com/content/pdf/10.1186/s13045-018-0693-2.pdf> DOI: 10.1186/s13045-018-0693-2
- [XP] TANG BIXIA ET AL: "Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial", CLINICAL CANCER RESEARCH, vol. 26, no. 16, 14 August 2020 (2020-08-14), US, pages 4250 - 4259, XP093126887, ISSN: 1078-0432, Retrieved from the Internet <URL:https://aacrjournals.org/clincancerres/article-pdf/26/16/4250/2061090/4250.pdf> DOI: 10.1158/1078-0432.CCR-19-3922
- [Y] YARCHOAN MARK ET AL: "Tumor Mutational Burden and Response Rate to PD-1 Inhibition", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 377, no. 25, 21 December 2017 (2017-12-21), US, pages 2500 - 2501, XP093126894, ISSN: 0028-4793, DOI: 10.1056/NEJMc1713444
- [Y] MANDALÀ MARIO ET AL: "PD-L1 in melanoma: facts and myths", MELANOMA MANAGEMENT, vol. 3, no. 3, 1 September 2016 (2016-09-01), pages 187 - 194, XP093126896, ISSN: 2045-0885, DOI: 10.2217/mmt-2016-0013
- See also references of WO 2021160151A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 4104856 A1 20221221; **EP 4104856 A4 20240626**; CN 113244386 A 20210813; CN 115052628 A 20220913; US 2023082898 A1 20230316; WO 2021160151 A1 20210819

DOCDB simple family (application)

EP 21753897 A 20210210; CN 202010090829 A 20200213; CN 2021076456 W 20210210; CN 202180013152 A 20210210; US 202117904096 A 20210210